

Factsheet FY/2014



COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 216,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	FY/2014	Change	FY/2013	Change
Sales and Earnings				
Sales	23,231	14%	20,331	5%
EBIT ¹	3,158	4%	3,045	-1%
Net income (before special items) ²	1,086	3%	1,051	12%
Earnings per ord. share in € (before special items) ²	2.01	3%	1.96 ⁶	8%
Balance sheet and cash flow				
Total assets	39,897	22%	32,758	7%
Non-current assets	29,869	21%	24,786	10%
Equity ³	15,483	17%	13,260	4%
Equity ratio ³	39%	--	41%	--
Net debt/EBITDA ⁴	3.41	--	2.51	--
Investments ⁵	3,795	-1%	3,827	-8%
Operating cash flow	2,585	11%	2,320	-5%
Operating cash flow in % of sales	11.1%	--	11.4%	--
Profitability				
EBIT margin ¹	13.6%	--	15.0%	--
Return on equity after taxes (ROE) ^{1,2}	11.6%	--	12.8%	--
Return on operating assets (ROOA) ⁴	9.1%	--	10.6%	--
Return on invested capital (ROIC) ⁴	7.5%	--	8.8%	--
Employees (December 31)	216,275	21%	178,337	5%

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

³ Including noncontrolling interest


⁴ 2014 pro forma acquisitions, before special items; 2013 pro forma excluding advances made in the amount of €2.18 billion under a fiduciary arrangement for the acquisition of hospitals of Rhön-Klinikum AG; before special items

⁵ Investments in property, plant and equipment, and intangible assets, acquisitions

⁶ Adjusted for 1:3 share split in 2014

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.



¹ As of December 31, 2014


BUSINESS SEGMENTS

€ in millions		FY/2014	Change	FY/2013	Change
	Sales	11,917	8%	11,000	2%
	EBIT	1,697	0%	1,699	-6%
	Sales	5,146	3%	4,996	10%
	EBIT ¹	873	-6%	926	-1%
	Sales	5,244	55%	3,393	6%
	EBIT	553 ¹	42%	390	21%
	Sales	1,042	2%	1,020	21%
	EBIT	59	7%	55	8%


¹ Before special items

- ▶ **Fresenius Medical Care** is the world's largest integrated provider of dialysis products and services. As of December 31, 2014, Fresenius Medical Care was treating 286,312 patients in 3,361 dialysis clinics.
- ▶ **Fresenius Kabi** offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- ▶ **Fresenius Helios** is Germany's largest hospital operator. HELIOS owns 110 hospitals, thereof 86 acute care clinics including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal and 24 post-acute care clinics. HELIOS treats more than 4.2 million patients per year, thereof more than 1.2 million inpatients, and operates more than 34,000 beds.
- ▶ **Fresenius Vamed** manages projects and provides services for hospitals and other health care facilities worldwide.

SALES BY REGION




SALES BY BUSINESS SEGMENT




FRESENIUS SHARE/ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (December 31, 2014)	541,532,600
Market capitalization (December 31, 2014)	€23.4 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX



DEVELOPMENT SHARE DIVIDENDS IN €¹



¹ 2005 – 2013 adjusted for share split

² Proposal

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Stephan Sturm, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Maturity
Fresenius Finance B. V.	XS1013954646	€300	2.375%	2019
Fresenius Finance B. V.	XS0759200321	€500	4.25%	2019
Fresenius Finance B. V.	XS0873432511	€500	2.875%	2020
Fresenius Finance B. V.	XS1013955379	€450	3.00%	2021
Fresenius Finance B. V.	XS1026109204	€450	4.00%	2024
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015
Fresenius US Finance II, Inc.	USU31436AG04	US\$300	4.250%	2021
Convertible bonds				
Fresenius SE & Co. KGaA	DE000A1YC3T6	€500	0.00%	2019

Bonds of Fresenius Medical Care can be found under [www.fmc-ag.com/Investor Relations\Credit Relations](http://www.fmc-ag.com/Investor%20Relations/Credit%20Relations).

SHARE PERFORMANCE¹

1 month	- 1,0%
4 th quarter	+ 10,1%
1 year	+ 16,0%
5 years	+ 198,0%
10 years	+ 420,4%

¹ Effective date/closing price: December 31, 2014

GROUP OUTLOOK 2015

	Targets 2015
Sales, growth (in constant currency)	7% – 10%
Net income ¹ , growth (in constant currency)	9% – 12%
Capital expenditure	~6% of group sales

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2015 before integration costs (~€10 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the efficiency program at Fresenius Kabi (~€100 million before tax) and before the gain from the divestment of two HELIOS hospitals (€34 million before tax); 2014 before special items

For the outlook of the business segments please see the Investor News of February 25, 2015.

FINANCIAL CALENDAR

	Dates
Report on 1 st quarter 2015	April 30, 2015
Annual General Meeting, Frankfurt/Main	May 20, 2015
Payment of dividend ¹	May 21, 2015
Report on 2 nd quarter 2015	July 30, 2015
Report on 3 rd quarter 2015	October 29, 2015

Please note that these dates could be subject to modifications.

¹ Subject to prior approval by the Annual General Meeting

CONTACT

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.

e-mail: ir-fre@fresenius.com

Internet: www.fresenius.com

Birgit Grund

Senior Vice President

Investor Relations

Telephone: ++49 61 72 6 08-24 85

Telefax: ++49 61 72 6 08-24 88

Leslie Iltgen

Vice President

Investor Relations

Telephone: ++49 61 72 6 08-44 78

Telefax: ++49 61 72 6 08-24 88